Thermo Fisher Scientific sells the tools, chemicals, and services that scientists need to do their work. Pharmaceutical companies use its reagents and instruments to discover new drugs. Hospitals use its diagnostic kits to test patients. Biotech firms hire its Patheon and PPD divisions to manufacture and run clinical trials for new medicines. The key to understanding the business is that most of what it sells gets used up and reordered. A lab does not buy a bottle of reagent once. It buys it every month, year after year. That recurring demand from four segments, Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services, is what makes the revenue engine tick. The diagram below traces where the money goes.
How Thermo Fisher Scientific Makes Money
flowchart TD
A["Customer Base
125,000 colleagues"] --> B["Four Business Segments"]
B --> C["Consumables & Reagents
18.7B"]
B --> D["Instruments & Equipment
7.3B"]
B --> E["Pharma & Lab Services
18.6B"]
C --> F["Direct Sales Force
14,000 sales staff"]
D --> F
E --> F
F --> G["Product & Service Revenue
44.6B"]
G --> H["R&D Investment
New products"]
H --> I["Portfolio Expansion
Organic and acquisitions"]
I --> C
I --> D
I --> E
G --> J["Operating Cash Flow
7.8B"]
J --> H
J --> K["Shareholder Returns
Capital allocation"]
L["Global Distribution
Thermo Scientific, Fisher"] --> F
M["Supply Chain
Raw materials"]
M --> C
M --> D
Five years of financial data tell a story in two chapters. The first chapter is a boom. In 2021 and 2022, revenue jumped to $39.2 billion and then $44.9 billion, driven in large part by COVID-19 related work including vaccine manufacturing and testing. Gross margins in 2021 reached above 50 percent, the highest in the five-year window, reflecting how profitable that pandemic-era demand was. The second chapter is a reset. When COVID-19 work faded, revenue fell back to $42.9 billion in both 2023 and 2024, and gross margins compressed to around 40 percent, where they have stayed. The business did not collapse, but it did settle at a lower level of profitability than the peak years suggested.
Annual Revenue 2021 to 2025 (in billions of dollars)
Revenue peaked in 2022 on COVID-19 tailwinds, then held roughly flat for two years before recovering toward $44.6 billion in 2025.
The recovery in 2025 is real but narrow. Revenue climbed back to $44.6 billion, and the company reported $7.8 billion in operating cash flow. The growth came mainly from the bioproduction business inside Life Sciences Solutions, which supplies materials used to manufacture biological drugs, and from the Laboratory Products and Biopharma Services segment. However, the Analytical Instruments segment, which sells tools like mass spectrometers and electron microscopes, saw its profit margin fall from 26.2 percent to 23.0 percent in 2025, partly because of tariffs and foreign exchange pressure. China, a historically important market, also saw declining sales. These two pressure points are worth watching.
$44.6B
Revenue in 2025, recovering from two flat years at $42.9 billion
What is free cash flow?
Free cash flow is the money left over after a company pays for its day-to-day operations and buys the equipment it needs to keep running. It is the cash available to pay down debt, make acquisitions, or return to shareholders. A company that consistently generates free cash flow has more options than one that does not.
One consistently strong signal in the data is free cash flow. The company generated between $6.8 billion and $7.3 billion in free cash flow every year from 2021 through 2024. In 2025 that number dipped to $6.3 billion, partly because working capital consumed more cash and income tax payments remained high at $1.78 billion. The company used much of its cash to keep acquiring businesses, spending $4.04 billion on acquisitions in 2025 alone, including the purchase of Olink, a proteomics company, in 2024, and a filtration and separation business from Solventum Corporation in 2025. These deals expand capability but they also add debt. Net debt rose to $29.5 billion in 2025, up from $26.0 billion in 2022.
$49.4B
Goodwill on the balance sheet at December 31, 2025, reflecting decades of acquisitions
What is goodwill and why does it matter?
When a company pays more for an acquisition than the value of its physical assets, the extra amount is recorded on the balance sheet as goodwill. It represents the premium paid for things like customer relationships and brand names. If those acquired businesses perform worse than expected, the company may have to write down, meaning reduce, that goodwill balance, which creates a large one-time charge that hurts reported profits.
That $49.4 billion goodwill balance sits at the center of one of the company's most serious documented risks. Thermo Fisher has built its scale through acquisitions, which is an effective strategy in good times. But if acquired businesses underperform, regulators intervene, or interest rates make future deals harder to justify, the company may be forced to write off large portions of that goodwill. The 10-K filing notes that the filtration and separation business acquired in September 2025 carried $2.10 billion of goodwill and an overall carrying value of $4.01 billion, and that its fair value was not substantially above its carrying value at the time of the annual assessment. Small setbacks in that business could trigger an impairment charge.
2022
crisis
COVID Revenue Peak Masks Underlying Reset
In 2022, Thermo Fisher reported $44.9 billion in revenue and gross margins above 42 percent, boosted by COVID-19 vaccine manufacturing contracts and testing demand. When that work faded, revenue dropped to $42.9 billion and gross margins fell to around 40 percent, where they have remained. The company did not lose its core business, but the pandemic years created a high-water mark that took three years to approach again, making year-over-year comparisons look weaker than the underlying business actually was.
Beyond the balance sheet, three other risks stand out from the company's own disclosures. First, some materials used in manufacturing come from only one or two suppliers. If those suppliers fail, production stops. Second, the company holds sensitive research data and runs complex IT systems, making it a target for ransomware and cyberattacks. Third, it operates in roughly 70 countries, which exposes it to tariffs, trade restrictions, and geopolitical tension. The 2025 10-K specifically notes that tariffs hurt the Analytical Instruments segment's margins. The company also disclosed ongoing controversies related to the sale of DNA collection equipment to authorities in China, which created reputational and regulatory exposure that the 10-K does not fully quantify.
$29.5B
Net debt at end of 2025, up from $26.0 billion in 2022 as acquisitions continue
Thermo Fisher's revenues are historically stronger in the fourth quarter because pharmaceutical and government customers tend to spend their capital budgets at the end of the year. That seasonal pattern means any given quarter's results need to be read in context of the full year.
The Bet
Pharmaceutical and biotech companies keep increasing their spending on drug development and biological manufacturing at a pace that fills the gap left by fading COVID-19 related revenue. The entire growth case depends on bioproduction demand, proteomics tools, and outsourced pharma services growing fast enough to offset weakness in China, pressure on Analytical Instruments margins, and the rising cost of carrying nearly $30 billion in net debt. If pharma and biotech customers pull back spending, or if generic competition and drug pricing policies shrink their budgets, the demand that fills those four segments slows, and the acquisition-driven model that assumes steady cash generation to service debt and fund new deals comes under real stress.
Open question
Thermo Fisher has a large, diversified business that generates substantial cash and serves customers who genuinely need what it sells. But it also carries nearly $50 billion in goodwill, close to $30 billion in net debt, and a gross margin that has compressed by roughly 9 percentage points since 2021. The recovery in 2025 is encouraging, but it rests heavily on one segment and one customer type. Can pharma and biotech demand grow consistently enough to justify the debt load and goodwill on the balance sheet, or will the next spending slowdown in those markets expose how much of the current model depends on conditions staying favourable?
Compiled · 10-K · FY2025
Regulatory and Product Quality
Thermo Fisher manufactures pharmaceuticals and complex pharma services where even small quality failures can force destruction of entire batches or halt production. The FDA and other regulators can issue warnings, recalls, or seizures if quality standards aren't met, potentially costing millions in lost products and damaged customer relationships.
Supply Chain
Some materials come from only one or two suppliers due to quality or regulatory needs. If these suppliers fail, go bankrupt, or stop doing business, Thermo Fisher cannot quickly find replacements, which could halt production and prevent shipments to customers.
Cybersecurity
Thermo Fisher stores sensitive customer and employee data and relies on complex IT systems to run its business. Cyber attacks, ransomware, or data breaches could interrupt operations, expose trade secrets, damage customer trust, and trigger expensive lawsuits and regulatory fines.
Acquisition Integration and Asset Impairment
Thermo Fisher has acquired many companies and now carries approximately 49.36 billion dollars in goodwill and 1.23 billion dollars in intangible assets on its books. If these acquired businesses do not perform as expected, the company could be forced to write off billions of dollars.
International Operations and Tariffs
Thermo Fisher manufactures products and sources materials globally and sells in many countries. Tariffs, trade restrictions, currency swings, Chinese supplier requirements, and geopolitical tensions like wars or sanctions could disrupt supply chains, increase costs, and reduce profits.
10-K Item 1A · Risk Factors
